Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | APAF1 | O14727 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | TEAD4 | Q15561 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | CCNC | P24863 | 1/20 | 0.40 |
| ▸ | CDK8 | P49336 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17179266 | 0.83 | MEN1 (0.44) | MEN1APAF1KMT2ATEAD4ALDH1A1 | |
| SCHEMBL7997563 | 0.81 | PTGS1 (0.43) | MAPTTSHRSMN1; SMN2CCNCCDK8 | |
| SCHEMBL18418112 | 0.80 | MAPT (0.36) | MEN1KMT2AALDH1A1TDP1MAPT | |
| SCHEMBL4796326 | 0.79 | MEN1 (0.56) | MEN1APAF1KMT2ATEAD4ALDH1A1 | |
| SCHEMBL31179951 | 0.78 | TEAD4 (0.60) | MEN1APAF1KMT2ATEAD4ALDH1A1 | |
| SCHEMBL27944963 | 0.78 | PARP10 (0.46) | MEN1APAF1KMT2ATEAD4ALDH1A1 | |
| SCHEMBL18418110 | 0.77 | SLC6A4 (0.42) | MEN1KMT2AALDH1A1MAPTCYP3A4 | |
| SCHEMBL13603241 | 0.77 | ALDH1A1 (0.46) | MEN1APAF1KMT2ATEAD4ALDH1A1 | |
| SCHEMBL25873407 | 0.76 | HTT (0.50) | MEN1KMT2AALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL4799889 | 0.75 | TEAD4 (0.47) | MEN1APAF1KMT2ATEAD4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230374024-A1 | Compounds for the Treatment of Kinase-Dependent Disorders | EXELIXIS, INC. | 2023-11-23 | — | — | US | disclosed |
| US-11708367-B2 | Compounds for the treatment of kinase-dependent disorders | EXELIXIS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11708367-B2 | Compounds for the treatment of kinase-dependent disorders | ERBB2, ERBB3, MAP3K6 | MEN1 1849/4885APAF1 3129/4885KMT2A 1670/4885 |
| US-20230374024-A1 | Compounds for the Treatment of Kinase-Dependent Disorders | ERBB2, ERBB3, MAP3K6 | MEN1 1849/4885APAF1 3129/4885KMT2A 1670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.